Qualigen Therapeutics (QLGN) Competitors $3.10 -0.01 (-0.45%) As of 03/14/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends QLGN vs. ACXP, AIM, QNTM, TSBX, APLM, RLMD, ABVC, ADXN, OBSV, and AYTUShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Acurx Pharmaceuticals (ACXP), AIM ImmunoTech (AIM), Quantum Biopharma (QNTM), Turnstone Biologics (TSBX), Apollomics (APLM), Relmada Therapeutics (RLMD), ABVC BioPharma (ABVC), Addex Therapeutics (ADXN), ObsEva (OBSV), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Acurx Pharmaceuticals AIM ImmunoTech Quantum Biopharma Turnstone Biologics Apollomics Relmada Therapeutics ABVC BioPharma Addex Therapeutics ObsEva Aytu BioPharma Acurx Pharmaceuticals (NASDAQ:ACXP) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Does the MarketBeat Community prefer ACXP or QLGN? Acurx Pharmaceuticals received 8 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. Likewise, 93.75% of users gave Acurx Pharmaceuticals an outperform vote while only 87.50% of users gave Qualigen Therapeutics an outperform vote. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1593.75% Underperform Votes16.25%Qualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50% Do institutionals & insiders have more ownership in ACXP or QLGN? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 29.6% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate ACXP or QLGN? Acurx Pharmaceuticals presently has a consensus target price of $12.00, suggesting a potential upside of 2,503.04%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, ACXP or QLGN? Qualigen Therapeutics has higher revenue and earnings than Acurx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$1.09-0.42Qualigen Therapeutics$4.98M0.45-$13.42MN/AN/A Which has more volatility and risk, ACXP or QLGN? Acurx Pharmaceuticals has a beta of -1.71, meaning that its stock price is 271% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Is ACXP or QLGN more profitable? Qualigen Therapeutics' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -392.36% -223.78% Qualigen Therapeutics N/A N/A -424.18% Does the media prefer ACXP or QLGN? In the previous week, Acurx Pharmaceuticals had 4 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for Acurx Pharmaceuticals and 2 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 1.30 beat Acurx Pharmaceuticals' score of 0.29 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Acurx Pharmaceuticals Neutral Qualigen Therapeutics Positive SummaryAcurx Pharmaceuticals beats Qualigen Therapeutics on 9 of the 14 factors compared between the two stocks. Remove Ads Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.25M$7.03B$5.67B$8.13BDividend YieldN/A2.75%4.40%4.08%P/E RatioN/A6.2623.8119.04Price / Sales0.45232.36394.8188.14Price / CashN/A65.6738.0534.64Price / Book-0.156.596.834.29Net Income-$13.42M$142.18M$3.19B$247.40M7 Day Performance-1.92%-1.29%6.56%-0.85%1 Month Performance-17.50%-8.97%-0.36%-9.36%1 Year Performance-83.47%-6.25%11.95%4.03% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$3.06-1.6%N/A-84.9%$2.25M$4.98M0.0050Short Interest ↓Positive NewsACXPAcurx Pharmaceuticals2.5668 of 5 stars$0.45-1.6%$12.00+2,566.1%-83.0%$8.77MN/A-0.413Upcoming EarningsShort Interest ↑Gap UpHigh Trading VolumeAIMAIM ImmunoTech2.1907 of 5 stars$0.13-5.3%$2.75+2,082.5%-65.2%$8.66M$190,000.00-0.2720Positive NewsGap UpQNTMQuantum BiopharmaN/A$4.40-4.8%N/AN/A$8.44MN/A-0.29N/ATSBXTurnstone Biologics1.5882 of 5 stars$0.36-3.6%$0.45+25.1%-87.7%$8.32M$19.31M-0.1182Upcoming EarningsShort Interest ↑Gap DownAPLMApollomics2.965 of 5 stars$7.55+18.2%$200.00+2,549.0%-87.1%$8.21M$1.22M0.0045RLMDRelmada Therapeutics4.3476 of 5 stars$0.27-5.1%$4.25+1,462.5%-94.2%$8.21MN/A-0.0910Upcoming EarningsShort Interest ↓Gap DownABVCABVC BioPharma0.6005 of 5 stars$0.63-1.0%N/A-46.2%$8.21M$509,788.00-0.7430Short Interest ↑ADXNAddex Therapeutics2.7735 of 5 stars$7.50-2.7%$30.00+300.3%-34.7%$7.95M$556,045.00-22.0430Short Interest ↓Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageAYTUAytu BioPharma2.0946 of 5 stars$1.26+0.8%N/A-58.0%$7.77M$77.23M-0.87160Positive News Remove Ads Related Companies and Tools Related Companies ACXP Competitors AIM Competitors QNTM Competitors TSBX Competitors APLM Competitors RLMD Competitors ABVC Competitors ADXN Competitors OBSV Competitors AYTU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QLGN Stock Alerts